Research programme: HER3 receptor tyrosine kinase modulators - Celldex Therapeutics Inc
Latest Information Update: 06 Aug 2021
At a glance
- Originator MedImmune
- Developer Celldex Therapeutics Inc
- Class Monoclonal antibodies
- Mechanism of Action ERBB-3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics Inc
- 21 Jan 2014 This programme is still in active development